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Introduction
Immune deficiency has recently been identified as one of
the hallmarks of cancer, and as such, strategies that rectify
this are therapeutically attractive. A potential immu-
notherapy is IMM-101, which is a suspension of heat-
killed Mycobacterium obuense that has recently undergone
a Phase I trial of safety and tolerability in melanoma
patients (NCT01559819). It is also currently undergoing
Phase II trials in pancreatic cancer in combination with
Gemcitabine (NCT01303172) and colorectal cancer in
combination with radiation therapy (NCT01539824).
Methods
In the current study, two in vivo models were employed to
discern the action of IMM-101 on tumour growth and
metastatic potential. In the first model, either a colorectal
(CT26) or a melanoma (B16F10) tumour, sygeneic to the
BALB/c and C57BL/6 mouse, were used to assess the
effect of IMM-101 administered subcutaneously on
tumour growth. In the second model, CT26 were inocu-
lated into the tail vein of a BALB/c mouse to model the
effects of the agent on the metastatic potential of the
tumour. Methodologically, BALB/c mice were primed for
three weeks with CT26 lysate intraperitoneally and IMM-
101 subcutaneously prior to an intravenous challenge with
viable CT26 cells. The mice were then administered with
therapeutic subcutaneous IMM-101 for the following
three weeks, and metastatic burden in the lungs measured
on day 42.
Results
Results from the subcutaneous model showed IMM-101
had no significant effect on tumour growth in both the
colorectal and melanoma tumours. For example, mean +/-
SD of the area under curves for the growth of CT26
tumours in control and IMM-101 treatment groups were
13,798 +/- 4,608 and 20,877 +/- 10,259, respectively;
p = 0.062. However, in the second model, there was a
significant reduction in the number of lung metastatic
lesions in those mice primed with tumour lysate and
IMM-101 and then further treated with IMM-101
(mean +/- SD of the number of lung metastases were
1.8 +/- 2.9 vs. 19 +/- 18 for controls where mice were only
primed with tumour lysate; p < 0.01). Furthermore, sple-
nocytes harvested from these mice displayed significantly
enhanced production of IFN-g, IL-17 and GMCSF in
response to in vitro stimulation with anti-CD3.
Conclusions
These data from in vivo models suggest that IMM-101
has a greater effect on the metastatic capacity of tumour
cells rather than on overall tumour growth. Intriguingly,
this mimics other pre-clinical observations that suggest
IMM-101 is efficacious against metastasis.
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